中银国际研究报告指，三生制药(01530.HK) 日前公布与辉瑞(PFE.US) 就PD-1/VEGF双特异性抗体(SSGJ-707)达成中国以外的全球许可转让合作，交易包括12.5亿美元(下同)的许可首付款付款、最多48亿元的里程碑付款，以及双位数百分比的分级销售里程碑付款。此外，辉瑞可能会认购价值1亿元的三生制药普通股。
该行认为交易规模超出市场预期，将交易前期款项纳入集团2025财年的收入预测，并将SSGJ-707在2029财年之后的海外贡献纳入评估范围，目标价由12.7元上调至21.8元，维持“买入”评级。(ss/j)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-21 12:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.